Results 291 to 300 of about 1,646,961 (327)

Tissue Stem Cell-Based Therapies in Parkinson’s Disease: A Scoping Review of Therapeutic Mechanisms and Translational Outcomes

Emily Cueva, Andrea Wiesheu, Zaira Sordo, J. Patrick Gonzalez, S Falconi, José A. Rodas, José E. León-Rojas   +6 more
openalex   +1 more source

A Narrative Review on Efficacy of Cell‐ and Tissue‐Based Therapies for Diabetic Foot Ulcer [PDF]

Advanced Therapeutics
AbstractDiabetic foot ulcers (DFUs) are complex, making conventional treatments challenging in restoring skin tissue. Stem cell therapy (SCT) and skin replacement therapy (SRT) offer promising solutions by addressing prolonged inflammation, impaired cell proliferation, and reduced extracellular support.
Behnaz Niroomand, Ibrahim Mohammadzadeh, Maryam Tabarzad, Elham Mohit   +3 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Regenerative Cell and Tissue-based Therapies for Pulmonary Arterial Hypertension

Canadian Journal of Cardiology, 2014
Within the span of 2 decades, cell-based regenerative therapies for pulmonary arterial hypertension have progressed from bench-side hypotheses to clinical realities. Promising preclinical investigations that examined the therapeutic potential of endothelial progenitor cell and mesenchymal stem cell populations have demonstrated the safety and efficacy ...
William S, Foster, Colin M, Suen, Duncan J, Stewart   +2 more
openaire   +2 more sources

Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study

Indian Journal of Cancer, 2017
Resistance to 1st or 2nd generation epidermal growth factor receptor (EGFR) - tyrosine kinases (TKIs) develops predominantly due to an acquired mutation, EGFR T790M. Third-generation EGFR-TKIs have demonstrated potent activity against TKI resistance mediated by EGFR T790M.
R, Mistry, A, Patil
openaire   +2 more sources

Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore

2015
The regulatory environment for cell- and tissue-based therapeutic products and gene therapy products is rapidly evolving and drug regulatory agencies are working towards establishing a risk-based system in the regulatory framework. Similarly in Singapore, a risk-based tiered approach has been applied whereby clinical trials and product licence of high ...
Choon Wee, Goh, Srinivasan N, Kellathur, Lee Lee, Ong, Xiaofeng, Wu   +3 more
openaire   +2 more sources

Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea

Tissue Engineering Part A, 2015
Extensive investment on research and development of cell therapy products (CTPs) and tissue-engineered products (TEPs) has been made in Korea, and various commercial products are born in market. The Ministry of Food and Drug Safety (MFDS) in Korea regulates CTPs and TEPs as biological products under the authority of the Pharmaceutical Affairs Act.
openaire   +2 more sources

Regulatory Framework for Cell and Tissue Based Therapies in Europe

2016
Whereas some basic therapies based on tissues and cells have been in clinical use for years, advances in regenerative medicine present new challenges and new types of products for regulation. This article focuses on cell therapies which can be classified as medicinal products across the European Union.
Gudrun Tiedemann, Sebastian Sethe
openaire   +1 more source